Malaria Infections and Infestations Unspecified malaria
Conditions
Interventions
As part of routine treatment, participants are treated with seasonal malaria chemoprevention (SMC) drugs (unique dose of sulfadoxine-pyrimethamine and one dose of amodiaquine on the first day and two
Sponsors
Institut de Recherche en Sciences de la Santé
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Both sexes 2. Resident of the study area 3. Willingness to remain in the study area during the study 4. Age between 3 and 59 months 5. Provision of signed informed consent 6. Absence of severe malnutrition or severe condition
Exclusion criteria
Exclusion criteria: 1. Absence of provision of informed consent 2. Age less than 3 months and more than 59 months 3. Presence of severe malnutrition or other severe condition 4. Residing outside the study area
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of children aged 3 - 59 months (at the time of first SMC cycle) who received five monthly treatments of SMC measured using patient records one month after the last round of treatment (in December) | — |
Secondary
| Measure | Time frame |
|---|---|
| All measured one month after the last round of treatment (in December) unless otherwise noted: 1. The proportion of children 3 - 59 months (at the time of SMC first cycle) who received 1, 2, 3, 4 or 5 monthly treatments of SMC measured using patient records through coverage survey 2. Logistics of delivery including the number of health workers, the time required per month, the average number of children treated per health worker team measured using qualitative and quantitative surveys 3. Timeliness of delivery measured using individual interview 4. Quality of delivery (adherence to guidelines) measured using using individual interview 5. Adherence to supervised and unsupervised doses measured using coverage survey 6. Acceptability to caregivers and to health staff measured using qualitative acceptability questionnaire 7. Prevalence of parasite carriage on baseline and at the end of the fifth cycle measured using epidemiological survey 8. Prevalence of molecular markers conferring resistance to SMC drugs (codons at dhfr, dhps, pfmdr-1 and pfcrt T76) measured using epidemiological survey | — |
Countries
Cote d'Ivoire
Outcome results
None listed